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In Phase II oncology trials, targeted therapies are being
constantly evaluated for their efficacy in specific popula-
tions of interest. Such trials require designs that allow for
stratification based on the participants’ biomarker signature.
One of the disadvantages of a targeted design (defined
as enrichment in biomarker-positive sub-population) is
that if the drug has at least some activity in the biomarker-
negative subjects, then their effect in the biomarker-
negative population may never be known.
Jones and Holmgren (JH) have proposed a design to
determine whether drug has activity only in target popula-
tion or the general population. Their design is an enrich-
ment adaptation based on two parallel Simon two-stage
designs. Unfortunately, there are several pitfalls in the JH
design: the issue of hypothesis testing is not properly
addressed and the type I error, power calculations and
expected sample size formulae are wrong too.
We study the JH design in detail, appropriately control
the type I and type II error probabilities that yield novel
optimal designs. We also discuss various alternative
Family Wise Error Rates (FWER) and the Individual
Hypothesis (IH) error rates in the weak sense as well as
the strong sense.
For each option of the error controls, we search for
designs over a 10 trillion search space and obtain opti-
mal designs that minimise the expected sample size. For
the particular example trial that JH consider, our opti-
mal design requires 38% fewer subjects in comparison
with the two parallel Simon two-stage design thereby
offering substantial efficiency in terms of the expected
sample size. In conclusion, our rectified design provides
a robust framework for adaptive enrichment in biomar-
ker-stratified Phase II trial design.
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